− EDUCATION To develop a machine learning (ML)-based predictive model for assessing the risk of zero-dose children using…+ HEALTH Chronic kidney disease (CKD) presents a growing public health challenge in China, exacerbated by low patient…+ POLICY Digital transformation in pharmaceutical regulatory affairs is accelerating as global submissions grow in com…− HEALTH The objective of this study is to develop and validate a Picture Archiving and Communication System-integrate…− HEALTH Artificial intelligence (AI) is increasingly used in cerebral small vessel disease (CSVD) imaging, but the ex…− HEALTH Background Large language models (LLMs) are increasingly accessed by patients for gastrointestinal health inf…− HEALTH Artificial intelligence in ophthalmology encounters a continual challenge: Systems proficient in picture clas…− HEALTH The FDA received a malfunction report involving Inogen one g5 oxygen concentrator, made by Inogen, Inc.. Rece…
TruaceTracing the truth around AISunday, September 20, 2026
Subscribe
TRV-2026-1134Certified recordPeer-reviewed

How to apply artificial intelligence (AI) to facilitate and enhance MASH trials

Introduction Metabolic dysfunction-associated steatohepatitis (MASH) is one of the most common liver diseases, but thus far only two drugs (resmetirom and semaglutide) have received conditional approval for use. Successful MASH trials are thus highly desired to fill the therapeutic and evidence gap. Concurrently, AI has powered advances in multiple areas of medicine. We consider in this review the potential applications of AI to enhance MASH trials. Methods We conduct a narrative review of AI uses in MASH, with…

Health · G Space — documented gain · certified 2026-09-18 · v1 · article view · machine-readable

Current reading — gain

AI-based digital pathology models have been qualified by regulators for endpoint determination in MASH trials, with additional AI risk models and large language models applied to patient enrollment, recruitment and retention.

What this doesn’t fix

Evidence is presented as a narrative review of current and potential applications, not as new trial results measuring safety or efficacy outcomes.

Evidence

Reader signal

How should this claim be treated?

Cite this record

Truvace Impact Record TRV-2026-1134, v1: “How to apply artificial intelligence (AI) to facilitate and enhance MASH trials.” Truvace, 2026-09-18. /record/TRV-2026-1134 (accessed at citation time). sha256 c8916e57b4e9509a…

Calibration history

Every change to this record since certification, in the open. None yet — the reading has held since it entered the record.

  1. Certifiedv1c8916e57b4e9…

    Certified into the record

Verify this record
How to verify without trusting this page

Fetch the canonical text of any version from /api/record/TRV-2026-1134 and hash it yourself — for example shasum -a 256 on the saved canonical field. The result must equal content_hash, and each version’s text ends with prev:followed by the prior version’s hash (version 1 chains to 64 zeros). If a single character of any version had been altered since certification, the chain would not reproduce.